Previous 10 | Next 10 |
Image source: The Motley Fool. CorMedix Inc Common Stock (NASDAQ: CRMD) Q4 2020 Earnings Call Mar 30, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: CorMedix Inc Common Stock (CRMD) Q4 2020 Earnings Call Transcript...
CorMedix Inc. (CRMD) Q4 2020 Earnings Conference Call March 30, 2021 04:30 PM ET Company Participants Dan Ferry - Investor Relations Khoso Baluch - Chief Executive Officer Phoebe Mounts - Executive Vice President & General Counsel Matt David - Executive Vice President & Chief Financia...
Gainers: [[ELOX]] +19.9%. [[SURF]] +15.0%. [[EVK]] +14.3%. [[EQ]] +10.4%. [[HYFM]] +9.2%.Losers: [[EDAP]] -7.4%. [[IMVT]] -5.3%. [[BYND]] -4.8%. [[CRMD]] -4.8%. [[OSMT]] -3.7%. For further details see: ELOX, SURF, EDAP and IMVT among after-hours movers
CorMedix (CRMD): Q4 GAAP EPS of -$0.19 beats by $0.03.Net loss of $6.1MRevenue of $0.06M (+200.0% Y/Y) beats by $0.02M.Khoso Baluch, CorMedix CEO commented, “While we were disappointed that the DefenCath NDA was not approved at its PDUFA date, we remain confident in our efforts to brin...
BERKELEY HEIGHTS, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for ...
Gainers: [[TLS]] +21.3%. [[IMMP]] +13.1%. [[PRTK]] +6.5%. [[WIMI]] +3.8%. [[YY]] +3.4%.Losers: [[CRMD]] -8.9%. [[SYBX]] -5.3%. [[PRQR]] -4.7%. [[CD]] -4.6%. [[OLK]] -3.9%. For further details see: TLS, IMMP, CRMD and SYBX among after-hours movers
BERKELEY HEIGHTS, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report it...
BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has been appro...
CRMD received a CRL that looks resolvable. The Defencath system has seen solid data. There are some negatives; however, the pros outweigh the risk. For further details see: CorMedix: Resolvable CRL And Low Price Make It Attractive
BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has entered in...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath ® (tauroli...
BERKELEY HEIGHTS, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has...